# Compassion vs Control: FDA Investigational-Drug Regulation 

May 20, 1986 • Policy Analysis No. 72 

By Dale H. Gieringer 

[ 

Download PDF 

](https://www.cato.org/sites/cato.org/files/pubs/pdf/pa072.pdf) 

“The basic problem is, I don’t have as much control over what I can do to get well as I want.”

> *–AIDS patient\[1\]*
> 
> “I think the FDA should recognize its responsibility for the denial of lifesaving technology.”
> 
> *–Robert Jarvik, developer of the artificial heart\[2\]*

[![Media Name: pa072.jpg](/sites/cato.org/files/styles/serial_cover_phone/public/pubs/covers/pa072.jpg?itok=CLwe9H49)](https://www.cato.org/sites/cato.org/files/pubs/pdf/pa072.pdf) 

### Download This Policy Analysis

##### Compassion vs Control: FDA Investigational-Drug Regulation 

[ 

Download PDF 

](https://www.cato.org/sites/cato.org/files/pubs/pdf/pa072.pdf) 

##### About the Author 

Dale H. Gieringer is a writer and policy analyst affiliated with the Decisions and Ethics Center of Stanford University. 

[![Creative Commons License](/build/cato_2020/images/creative-commons.svg)](http://creativecommons.org/licenses/by-nc-sa/4.0/) 
This work is licensed under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/). 

[ 

Download PDF 

](https://www.cato.org/sites/cato.org/files/pubs/pdf/pa072.pdf)